In 2021, the cardiac biomarkers industry contributes $8,459.6 million, and it is projected to rise at a rate of 10.5%, to capture $20,718.8 million revenue in 2030. It is led by the rising prevalence of acute coronary syndrome, increasing point-of-care testing kit demand, and technological advancements in the industry.
Moreover, the surging investments in biomarker research, increasing CVDs incidences, and rising geriatric population are projected to boost the industry growth.
Troponin holds a significant share of the industry, accounting for 35%, and it is projected to experience significant growth in the coming years. It is due to extraordinary specifications, and protein complex capacity to help in diagnosing cardiac problems, such as ACS, precisely.
In addition, the growing incidences of myocardial infarction proliferate the industry led by the wide usage of the troponin to diagnose this condition. Moreover, myocardial creatine kinase is projected to experience the next-significant growth after troponin, in the coming future.
Moreover, the cardiac test kits offer a variety of combined tests for identifying the presence of biomarkers, providing ease in cardiac disorders identification. In addition, the rising demand for these kits is led by fast diagnosis facilitated by them and thus enabling early treatment.Furthermore, they offer chest discomfort diagnosis with the easy identification of risk factors before it turns out to be a major cardiac event.
Around 18 million deaths worldwide are caused by cardiac vascular diseases each year, which accounts for 31% of all fatalities. Therefore, companies are focusing to offer test kits to facilitate the biomarkers detection for a better understanding of CVDs pathogenesis. Some of the major biomarkers are C-reactive protein (CRP), lipoprotein-associated phospholipase A2, N-terminal prohormone BNP, and cystatin C. Moreover, the surging use of biomarkers in ACS diagnosis and risk assessment proliferates the industry growth.
In addition, laboratory testing captures a substantial share of the industry, accounting for 60%, and it is projected to retain its position in the near future. It is led by increasing healthcare expenditure, reforms for improving the healthcare infrastructure, surging disposable incomes as well as initiatives of private and government sectors for the prevention of heart diseases.
Moreover, point-of-care testing is projected to experience substantial growth in the near future, led by its increased adoption by healthcare professionals for patient monitoring, in cases of chest pain in critical care centers.
In addition, myocardial infarction contributes significant revenue, accounting for $3.0 billion, and it is projected to retain its position in the near future. It is attributed to its rising prevalence due to lifestyle changes, including unhealthy food consumption, and excessive smoking, along with coronary artery disease.
Moreover, the growing demand for biomarker tests for early diagnosis of conditions that may cause a major cardiac event leads to cardiac biomarkers industry propulsion.
Furthermore, North America captures the largest share of the cardiac biomarkers industry, accounting for 35%. It is ascribed to the extensive precision medicine usage of the biomarkers, and growing adoption of biomarkers for cardiac disease diagnosis.
Therefore, the rising prevalence of CVDs, with growing incidences of death caused by heart failures, leads to increasing demand for cardiac biomarkers for early diagnosis of the conditions.